CP93129二盐酸盐 | 127792-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: CP93129二盐酸盐
• 英文名称: 1,4-dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-5H-pyrrol[3,2-b]pyridin-5-one
• 英文别名: CP 93129；3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one；3-(1,2,3,6-tetrahydropyridin-4-yl)-1,4-dihydropyrrolo[3,2-b]pyridin-5-one
• CAS: 127792-75-0
• 化学式: C₁₂H₁₃N₃O
• 分子量: 215.255
• InChiKey: PJYVGMRFPFNZCT-UHFFFAOYSA-N

物化性质

• 熔点：
  248 °C
• 沸点：
  531.5±50.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  56.9
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-氯-5-硝基吡啶 在 palladium on activated charcoal 盐酸 、 potassium tert-butylate 、 氢气 、 sodium 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， -10.0~60.0 ℃ 、303.98 kPa 条件下， 反应 89.0h， 生成 CP93129二盐酸盐
  参考文献：
  名称：

  3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1*) agonist and rotationally restricted phenolic analog of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole

  摘要：

  The synthesis and in vitro and in vivo characteristics of 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one (1, CP-93,129) are described. This rotationally restricted phenolic analogue of RU-24,969 is a potent (15 nM) and selective (200x vs the 5-HT1A receptor, 150x vs the 5HT1D receptor) functional agonist for the 5-HT1B receptor. Direct infusion of 1 into the paraventricular nucleus of the hypothalamus of rats significantly inhibits food intake, implicating the role of 5-HT1B receptors in regulating feeding behavior in rodents. 3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one (1) has also been shown to be biochemically discriminatory in its ability to selectively inhibit forskolin-stimulated adenylate cyclase activity only at the 5-HT1B receptor. The source of the selectivity of 1 appears to lie in the ability of a pyrrolo[3,2-b]pyrid-5-one to act as a rotationally restricted bioisosteric replacement for 5-hydroxyindole.

  DOI：

  10.1021/jm00170a007

文献信息

• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Kõster Hubert

  公开号：US20100248264A1

  公开（公告）日：2010-09-30

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

  提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
• Treatment for Attention-Deficit Hyperactivity Disorder
  申请人：Psychogenics Inc.

  公开号：EP2036547A2

  公开（公告）日：2009-03-18

  A solid dosage form comprising eltoprazine or pharmaceutically acceptable salt thereof for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity.

  一种包含埃托拉嗪或其药学上可接受的盐的固体制剂，用于治疗人类的注意力缺陷/多动障碍（ADHD）以及与之相关的症状、注意力不集中、多动并伴有冲动。
• Treatment for attention-deficit hyperactivity disorder
  申请人：——

  公开号：US20030050308A1

  公开（公告）日：2003-03-13

  A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided.

  本研究提供了一种利用埃托拉嗪和相关化合物治疗人类注意力缺陷/多动障碍（ADHD）及其相关症状、注意力不集中和多动冲动的方法。
• Fast-dispersing dosage form containing 5-HT1 agonists
  申请人：——

  公开号：US20040023948A1

  公开（公告）日：2004-02-05

  This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT 1 agonist, characterized in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT 1 agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.

  本发明涉及一种口服药物组合物，该组合物由载体和作为活性成分的 5-HT 1 激动剂，其特征在于该组合物的配制可减少所述 5-HT 1 激动剂。本发明还提供了制备这种组合物的工艺以及这种组合物用于治疗焦虑症、抑郁症、注意力缺陷障碍和/或恐慌症和/或作为记忆增强剂的用途。
• Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia
  申请人：Masferrer L. Jaime

  公开号：US20050085477A1

  公开（公告）日：2005-04-21

  The present invention provides compositions and methods for the treatment of neoplasia in a subject. More particularly, the invention provides a combination therapy for the treatment of a neoplasia comprising the administration to a subject of a serotonin modulating agent in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了用于治疗受试者肿瘤的组合物和方法。更具体地说，本发明提供了一种治疗肿瘤的组合疗法，包括向受试者施用5-羟色胺调节剂与环氧化酶-2选择性抑制剂。